email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1816 - 1830
of 3615 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Harbour Biomed Approved for China Phase II/III Trials of Graves' Ophthalmopathy Treatment
$5.00
Available
Nanjing Legend Biotech Plans to Raise $350 Million in US IPO at $2.6 Billion Valuation
$5.00
Available
Genor Bio Closes $160 Million B Round to Develop Ten Biologic Clinical Candidates
$5.00
Available
Jacobio, a Beijing Pharma, Out-Licenses Two SHP2 Candidates to AbbVie
$5.00
Available
Kintor Pharma Stages $240 Million Hong Kong IPO for Androgen Receptor Drugs
$5.00
Available
MGI Tech, a BGI Subsidiary, Raises $1 Billion to Make Gene Sequencing Machines
$5.00
Available
I-Mab Starts Phase Ib Trial of Re-purposed RA Treatment for COVID-19
$5.00
Available
Mabspace Reports Positive Data from Phase I Trial of 2nd-Gen PDL1
$5.00
Available
Immunochina and EdiGene Team Up to Discover Allogeneic T-Cell Therapies
$5.00
Available
CStone Reports Updated Data from Phase I trial of anti-PD-L1 mAb in NSCLC
$5.00
Available
Burning Rock of Guangzhou Plans $100 Million IPO on NASDAQ
$5.00
Available
Innovent's IBI939 is First TIGIT Inhibitor to Start China Trials
$5.00
Available
CanSino Publishes Positive Data from COVID-19 Vaccine Trial in The Lancet
$5.00
Available
Apollomics Starts Global Phase II Trial of c-MET Inhibitor
$5.00
Available
Peijia Medical Raises $302 Million in Hong Kong IPO for Medical Devices
$5.00
Available